| Autor: |
Detry O; Service de Chirurgie abdominale et Transplantation, CHU Liège, Belgique., Troisfontaine F; Service d'Oncologie médicale, CHU Liège,Belgique., Meurisse N; Service de Chirurgie abdominale et Transplantation, CHU Liège, Belgique., Delwaide J; Service d'Hépato-Gastroentérologie, CHU Liège,Belgique., Lamproye A; Service d'Hépato-Gastroentérologie, CHU Liège,Belgique., Warling O; Service d'Hépato-Gastroentérologie, CHU Liège,Belgique., Jadoul A; Service de Médecine nucléaire et d'Imagerie oncologique,CHU Liège, Belgique., Loly C; Service d'Hépato-Gastroentérologie, CHU Liège,Belgique., Collignon J; Service d'Oncologie médicale, CHU Liège,Belgique. |
| Abstrakt: |
In Belgium and around the world, the incidence of primary malignant liver tumours is increasing, both for hepatocarcinoma and cholangiocarcinoma. Their curative treatment is based on multidisciplinary and specialized care, of which surgery (including liver transplantation) remains the cornerstone, often associated with other logoregional treatments, as radioembolisation, radiofrequency ablation, and chemoembolisation. For advanced cases, the prognosis remains poor, in particular due to a certain chemoresistance of these tumours. New treatments include targeted therapies (including various tyrosine kinase inhibitors) and immunotherapy. A specialized multidisciplinary discussion is therefore necessary to define the best therapeutic management, individualized to each patient. In this article, the authors review the most recent data relating to the treatment of hepatocarcinoma and cholangiocarcinoma. |
